September 12, 2026
When a stock is up 380% in a year, even old news moves it. Here’s what that tells traders about momentum and risk.
Friday’s session handed traders one of the clearest momentum lessons of the year. Moderna gained roughly 8% on September 11 to close near $147, while its two closest cancer-vaccine rivals, Merck and BioNTech, barely registered a move. There was no new company announcement. No data. No pipeline surprise. The stock moved because Moderna is exactly the kind of name that moves when momentum already owns the room.
IPO Insider Warns: “Avoid OpenAI and Anthropic’s IPOs! Until You See This”
IPO insider, Jason Bodner, reveals how ordinary investors could risk their retirement if they invest in OpenAI and Anthropic’s IPOs the wrong way.
But if you make this one small change, you could potentially set up a six-figure nest egg.
What Happened
Argus upgraded Moderna to Buy from Hold with a $180 price target. That was the proximate catalyst Friday morning. But the upgrade was itself downstream of a much larger event that had already priced in a big part of the story weeks earlier.
On August 19, Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene in combination with Keytruda in patients with completely resected stage IIB-IV melanoma, with the trial meeting its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. That represented the first positive Phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer therapy. The global, double-blind trial randomized 1,137 resected stage IIB-IV patients. Moderna surged roughly 177% that single day. The Argus upgrade Friday simply gave traders a fresh reason to add.
Meanwhile, BioNTech’s competing program delivered the opposite verdict. BioNTech said it decided to terminate its Phase 2 clinical trial evaluating autogene cevumeran as adjuvant monotherapy in patients with resected colorectal cancer, after an independent Data Safety Monitoring Board recommended discontinuation. Analysts said the failure is a negative signal for mRNA vaccines in “cold” tumors historically resistant to immunotherapy, like colorectal and pancreatic cancers, unlike “hot” tumors such as melanoma where Moderna succeeded. With BioNTech’s program shuttered, the field’s best clinical evidence belongs entirely to Moderna and Merck, which concentrates capital and momentum in one direction.
430+ Gigawatts in Power Requests, One Company is Developing It
Large electricity users across Texas have requested more than 430 gigawatts of new grid power. That’s nearly 5x the state’s current peak capacity. American PowerGen is developing a 22 gigawatt natural gas pipeline across 16 projects, with 3 gigawatts of construction starting in 2027 and land, gas, and permits already secured on its lead projects. Shares are $2.50, $1,000 minimum.
Invest by September 30 to earn up to 17% bonus shares
Disclosure: This communication relates to a Regulation CF offering. Please review the offering materials, risk factors and required disclosures before making any investment decision.
Why It Happened
The divergence between MRNA and BNTX on Friday is not a mystery. Moderna received several analyst upgrades following positive trial results for its intismeran platform in adjuvant melanoma treatment, with Wolfe Research upgrading Moderna to Peerperform from Underperform and highlighting a clearer regulatory path with estimated peak sales of $9.2 billion across four indications. When a stock is already up several hundred percent on the year and analyst upgrades keep arriving, even incremental catalysts become amplified. Institutions chasing performance, short sellers covering, and options activity all compound the move.
Intismeran will be going after a share of a currently $2 billion to $3 billion U.S. melanoma therapeutics market growing at about 10% annually. That addressable market is real, but the stock had already priced in a substantial portion of the good news before Friday opened.
How Professionals Might View It
Disciplined traders distinguish between owning a scientific breakthrough and renting momentum. These are different positions requiring different rules.
The INTerpath-001 data is genuinely historic. Intismeran is manufactured from each patient’s tumor, encoding up to 34 neoantigens intended to drive tumor-specific T-cell responses after antigen presentation. No mRNA cancer therapy had cleared Phase 3 before this one. That matters scientifically. But a stock up roughly 380% on the year, still burning cash, with second-quarter revenue around $0.1 billion and a GAAP net loss of about $0.8 billion while targeting cash-flow breakeven by 2028, is not a value position. It is a momentum position. Those carry different exit strategies.
Nuclear Energy’s Comeback Could Spark Before 2026
Global energy demand is surging and one overlooked power source is quietly returning to the spotlight. New policy support and supply constraints are setting the stage for a surprising shift in the energy markets.
The contrast with Merck is instructive. MRK barely moved Friday despite being an equal partner in intismeran. Merck is a roughly $350 billion company; one cancer program, even a landmark one, does not move the needle. Moderna at its current size is almost entirely intismeran in the market’s eyes. That concentration cuts both ways.
What Comes Next
Moderna and Merck plan to seek FDA approval based on the drug’s results, though they have not announced a specific filing date. Moderna’s next earnings report is scheduled for October 29, 2026. Both events will test whether the market’s enthusiasm holds or whether the stock begins discounting the long road between Phase 3 results and commercial revenue.
The Trader’s Lesson
Momentum stocks do not need new reasons to move, they need enough participants who believe the next buyer is right behind them. Moderna on Friday was not trading on the Argus upgrade. It was trading on the weight of everything that had already happened, with the upgrade serving as permission. The lesson is not to chase or to fade reflexively. It is to know which game you are playing. Once a stock has become a momentum trade, its daily moves answer to positioning and sentiment, not to science. Size accordingly, define your exit before you enter, and never confuse a great drug with a safe stock price.